Mucosal healing effect of mesalazine granules in naproxen-induced small bowel enteropathy

Table 1 Baseline characteristics of the intent-to-treat patient population (n = 10)

Characteristic
Sex (female)	9
Age, yr (mean ± SD)	56.2 ± 9.7
Reason for NSAID therapy
Rheumatoid arthritis	2
Osteoarthritis	8
Medication use
Anti-hypertensive agents	3
Anti-diabetic agents	2
Low dose aspirin	NA
Statin	2

NA: Not available; NSAID: Non-steroidal anti-inflammatory drugs.

Table 2 Capsule endoscopy results according to Lewis Index Score evaluation of the small bowel mucosa at inclusion and 4 wk after mesalazine granules treatment

Subject No.	First tertile	Second tertile	Third tertile	Total LIS score
NSAID
1	429	3040	1404	3040
2	225	450	0	450
3	1630	225	225	1630
4	1462	204	1462	1462
5	247	247	0	247
6	1104	654	562	1104
7	1312	712	135	1312
8	361	0	0	361
9	1068	1068	225	1068
10	1690	393	135	1690
NSAID + mesalazine
1	900	1208	1237	1208
2	1462	165	0	1462
3	247	0	247	247
4	1068	339	1012	1068
5	112	0	0	112
6	1068	900	225	1068
7	1068	1068	233	1068
8	225	225	135	225
9	1104	0	0	1104
10	1690	1554	1104	1690

NSAID: Non-steroidal anti-inflammatory drugs; LIS: Lewis Index Score.

Table 3 Capsule endoscopy results of the patients with naproxen and naproxen + mesalazine granules therapy (n =10)

	Inclusion	After mesalazine gran therapy	P value
Total Lewis Index Score	1236.4 ± 821.9	925.2 ± 543.4	0.271
1st tertile	952.8 ± 584.9	894.4 ± 534.3	0.569
2nd tertile	699.3 ± 877.9	545.9 ± 580.9	0.649
3rd tertile	415.3 ± 561.5	319.3 ± 403.3	0.247
Ulcers with a diameter of > 3 mm, n
1st tertile	8	7	1.000
2nd tertile	8	6	0.625
3rd tertile	3	4	1.000
Gastric transit time (min)	43.8 ± 32	49.8 ± 35.6	0.470
Small bowel transit time (min)	261.9 ± 108	250.9 ± 93.9	0.470
Cleanliness score	1.3 ± 0.67	1.4 ± 0.69	0.345
Hemoglobin	131.1 ± 5.8	127.1 ± 7.8	0.103